Valneva to Host Investor Day in New York City
29 Novembre 2022 - 06:00PM
Live event and webcast December 6, 2022 10
AM – 12 PM ET
Saint-Herblain
(France), November 29,
2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a
specialty vaccine company, today announced it will host an
in-person investor day in New York City to discuss the Company’s
current vaccine pipeline, commercial products, and future
directions from 10:00 AM to 12:00 PM ET on Tuesday, December 6,
2022. The event will also be webcast live and archived on the
Company’s website.
Valneva’s Chief Executive Officer Thomas
Lingelbach, Chief Financial Officer Peter Bühler, and other members
of the Company’s senior leadership team will highlight Valneva’s
core near- and mid-term value drivers: its Lyme disease vaccine
candidate VLA15 (Phase 3, partnered with Pfizer), which is the only
Lyme vaccine program in advanced clinical development worldwide,
and its single shot chikungunya virus vaccine candidate VLA1553,
for which pre-commercial and market access preparations are ongoing
as rolling submission of a biologics license application (BLA) is
currently underway. Valneva will also provide an update on its
existing commercial business and select pre-clinical development
programs, followed by a financial overview.
A live Q&A session will follow the formal
presentations with opportunity for virtual attendees to participate
in the Q&A.
To register for the event, please click
here.
About Valneva SEValneva is a
specialty vaccine company focused on the development and
commercialization of prophylactic vaccines for infectious diseases
with significant unmet medical need. The Company takes a highly
specialized and targeted approach to vaccine development and then
applies its deep understanding of vaccine science to develop
prophylactic vaccines addressing these diseases. Valneva has
leveraged its expertise and capabilities both to commercialize
three vaccines and to rapidly advance a broad range of vaccine
candidates into and through the clinic, including candidates
against Lyme disease and the chikungunya virus.
Media
& Investor ContactsLaëtitia Bachelot-FontaineVP Global
Communications & European Investor RelationsM +33 (0)6 4516
7099
laetitia.bachelot-fontaine@valneva.com |
Joshua
Drumm, Ph.D.VP Global Investor RelationsM +001 917 815
4520joshua.drumm@valneva.com |
Valneva Forward-Looking
StatementsThis press release contains certain
forward-looking statements relating to the business of Valneva,
including with respect to its product candidates and estimates for
future performance. In addition, even if the actual results or
development of Valneva are consistent with the forward-looking
statements contained in this press release, those results or
developments of Valneva may not be sustained in the future. In some
cases, you can identify forward-looking statements by words such as
"could," "should," "may," "expects," "anticipates," "believes,"
"intends," "estimates," "aims," "targets," or similar words. These
forward-looking statements are based largely on the current
expectations of Valneva as of the date of this press release and
are subject to a number of known and unknown risks and
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievement expressed or implied by
these forward-looking statements. In particular, the expectations
of Valneva could be affected by, among other things, uncertainties
involved in the development and manufacture of vaccines, unexpected
clinical trial results, unexpected regulatory actions or delays,
competition in general, currency fluctuations, the impact of the
global and European credit crisis, and the ability to obtain or
maintain patent or other proprietary intellectual property
protection. Success in preclinical studies or earlier clinical
trials may not be indicative of results in future clinical trials.
In light of these risks and uncertainties, there can be no
assurance that the forward-looking statements made during this
presentation will in fact be realized. Valneva is providing the
information in these materials as of this press release and
disclaim any intention or obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise.
- 2022_11_29_VLA_Investor_Day_PR_EN_Final
Valneva (EU:VLA)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Valneva (EU:VLA)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024